Volume 10 Number 11/12 November/December 2009

12th European AIDS Society Conference (EACS) 11-14 November 2009, Cologne

EACS releases three updated management guidelines (December 2009)

11th International Workshop on Adverse Drug Reactions and Comorbidities in HIV (IWADR) 26-28 October 2009, Philadelphia

Intermuscular tissue is decreased in HIV infection

High incidence and risk factors for diabetes in French cohort

Gender and race differences in lipodystrophy symptoms

Lipodystrophy is common in children from three European cohorts

Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH

Reduced levels of vitamin D in patients taking efavirenz

Association between inflammation and sleep apnea in the MACS cohort

Sports supplements impact on serum creatinine and eGFR markers of renal function

9th AIDS Vaccine Conference 19-22 October 2009, Paris

Thai HIV Vaccine Trial results presented and published

49th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco

Smoking masks the long-term benefits of HAART on lung function

Recent ARVs and the blood/brain barrier: CSF drug concentrations of darunavir/r and raltegravir

Raltegravir body composition study: 48-week DEXA results

Alcohol and marijuana may reduce drug levels of atazanavir and efavirenz

Other drug interaction studies at ICAAC

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

Early infant diagnosis

Difficulties with implementation

Infant outcomes

Improved neurodevelopmental outcomes

Treating children exposed to single dose nevirapine for PMTCT

Using a nevirapine-containing fixed dose combination in the CHAPAS trial

Once a day lamivudine and abacavir, and abacavir hypersensitivity in the ARROW trial

AIDS and mortality in South Africa

Punishing success in tackling AIDS: funders retreat could wipe out health gains in HIV affected countries

Tibotec issues Dear Doctor letter in Europe concerning severe etravirine reactions: three case reports

GSK and Pfizer launch joint HIV collaboration

Rate of accumulation of TAMS slow in patients continuing on failing AZT or d4T containing regimens

Reduced etravirine levels after direct switch from efavirenz

Gemfibrozil significantly reduced by lopinavir/r

FDA approval of generic ARVs

Aging, HIV infection and the immune system

New neutralising antibodies discovered

The end of the line for IL-2

HIV, the brain and children

President Obama announces end to HIV-positive immigration ban in the US

BHIVA Autumn Conference and CHIVA Parallel Sessions

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts

WHO meeting: the impact of ARV treatment on prevention

JAIDS Supplement: HIV scale-up and global health systems

Returned to risk: deportation of HIV-positive migrants

UK patient survey: you, your GP and HIV

PLoS Medicine – November 2009

Volume 10 Number 11/12 November/December PDF

Volume 10 Number 9/10 September/October 2009

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

First results of new integrase compound: GSK1349572

Raltegravir in treatment-naive patients

Nevirapine vs atazanavir/ritonavir in treatment-naive patients: ARTEN study

Darunavir/r monotherapy studies

Maraviroc results similar to efavirenz when analysed using more sensitive tropism test

Lipid and metabolic changes with ARV combinations

Maximal suppression achieved with three drugs: no additional virological impact of raltegravir intensification

Tenofovir and renal safety

Time from seroconversion to treatment in Europe and Africa

Pharmacokinetics of atazanavir/ritonavir during pregnancy

Presentation with late stage HIV in women diagnosed during pregnancy

Low transmission rates and favourable pregnancy outcomes reported in the DREAM study

Pregnancy rates and outcomes among women in the DART trial

Pregnancy outcomes in HAART exposed infants in Johannesburg

Post navigation